Table 6. Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued.
| Drug | Mechanism of action | Phase | Study population | Clinicaltrials.gov Identification |
|---|---|---|---|---|
| Dovitinib | Multikinase inhibitor including FGFR1-3 | 2 | Refractory gastrointestinal stromal tumors | NCT01440959 |
| E7090 | FGF/FGFR pathway inhibitor | 1 | Refractory solid tumors dose expansion will enroll patients with tumor expressing genetic abnormality in FGF/FGFR pathway. | NCT02275910 |
| FGF401 | FGFR4-TKI | 1/2 | Hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and Klotho Berta (KLB) expression | NCT02325739 |
| FPA144 | FGFR2b antibody | 1 | Refractory solid tumors | NCT02318329 |
| GSK3052230 | FGF ligand trap (extra-cellular domain of FGFR1 fused with the Fc region of IgG1) | 1b | Refractory progressive sqNSCLC with FGFR1 gene amplification or MPM with measurable disease | NCT01868022 |
| INCB054828 | FGFR 1-3 TKI | 1 | Refractory solid tumors; on dose expansion subjects with sqNSCLC, gastric cancer, UC, endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR genes | NCT02393248 |
| JNJ-42756493 | Pan FGFR TKI | 2 | Metastatic or surgically unresectable UC that harbor specific FGFR genomic alterations | NCT02365597 |
| JNJ-42756493 | Pan FGFR TKI | 1 | Refractory HCC and for expansion phase participants must have FGF19 amplification in addition | NCT02421185 |
| JNJ-42756493 | Pan FGFR TKI inhibitor | 2a | Asian patients with advanced Non-small-cell lung cancer, urothelial cancer, gastric cancer, esophageal cancer or cholangiocarcinoma with FGFR gene mutation or translocation. | NCT02699606 |
| JNJ-42756493 | Pan FGFR TKI | 1 | Refractory solid tumors and lymphomas | NCT01962532 |
Abbreviations: Fibroblast growth factor (FGF), fibroblast growth factor receptor (FGFR), not reported (NR), estrogen receptor positive (ER+), tyrosine kinase inhibitor (TKI), bacillus calmette-Guerin (BCG), small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC), squamous non-small cell lung cancer (sqNSCLC), pilot study (PS), glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), Malignant pleural mesothelioma (MPM), immunohistochemistry (IHC), urothelial carcinoma (UC).www.clinicaltrials.gov accessed on April 22nd 2016.